Genomic characterization of childhood acute lymphoblastic leukemia

Seminars in Hematology

Volumn 50, Issue 4, 2013, Pages 314-324

  Mullighan, Charles G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; CYTOKINE RECEPTOR; IMATINIB; JANUS KINASE; PROTEIN CRLF2; RUXOLITINIB; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BCR ABL1 GENE; CANCER GENETICS; CHILDHOOD LEUKEMIA; CHROMOSOME 21; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CRLF2 GENE; EBF1 GENE; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HYPODIPLOID; IKZF1 GENE; LEUKEMIA RELAPSE; NUMERICAL CHROMOSOME ABERRATION; PAX5 GENE; PRE B LYMPHOCYTE; PRE T LYMPHOCYTE; PRIORITY JOURNAL;

ANIMALS; CELL LINEAGE; CHILD; GENOMICS; HUMANS; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84887539627     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.10.001     Document Type: Article

References (108)

1. Inaba H., Greaves M., Mullighan C.G. Acute lymphoblastic leukaemia. Lancet 2013, 381(9881):1943-1955.
2. Harrison C.J., Foroni L. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002, 6(2):91-113.
3. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N Engl J Med 2004, 350(15):1535-1548.
4. Wiemels J.L., Cazzaniga G., Daniotti M., et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999, 354(9189):1499-1503.
5. Raimondi S.C., Pui C.H., Head D.R., Rivera G.K., Behm F.G. Cytogenetically different leukemic clones at relapse of childhood acute lymphoblastic leukemia. Blood 1993, 82(2):576-580.
6. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446(7137):758-764.
7. Mullighan C.G., Miller C.B., Radtke I., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453(7191):110-114.
8. Mullighan C.G., Su X., Zhang J., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360(5):470-480.
9. Downing J.R., Wilson R.K., Zhang J., et al. The pediatric cancer genome project. Nat Genet 2012, 44(6):619-622.
10. Zhang J., Ding L., Holmfeldt L., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481(7380):157-163.
11. Holmfeldt L., Wei L., Diaz-Flores E., et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013, 45(3):242-252.
12. Andersson A.K., Ma J., Wang J., et al. Whole genome sequence analysis of 22 MLL rearranged infant acute lymphoblastic leukemias reveals remarkably few somatic mutations: a report from the St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project. ASH Annual Meeting Abstracts 2011, 118(21):69.
13. Roberts K.G., Morin R.D., Zhang J., et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012, 22(2):153-166.
14. Moorman A.V. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev 2012, 26(3):123-135.
15. Balgobind B.V., Raimondi S.C., Harbott J., et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009, 114(12):2489-2496.
16. Russell L.J., Capasso M., Vater I., et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114(13):2688-2698.
17. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41(11):1243-1246.
18. Dyer M.J., Akasaka T., Capasso M., et al. Immunoglobulin heavy chain (IGH) locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL): rare clinical curios or potent genetic drivers?. Blood 2010, 115(8):1490-1499.
19. Chapiro E., Radford-Weiss I., Cung H.A., et al. Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature. Cancer Genet 2013, 206(5):162-173.
20. Aifantis I., Raetz E., Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008, 8(5):380-390.
21. Bhojwani D., Pei D., Sandlund J.T., et al. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2012, 26(2):265-270.
22. Pui C.H., Campana D. Age-related differences in leukemia biology and prognosis: the paradigm of MLL-AF4-positive acute lymphoblastic leukemia. Leukemia 2007, 21(4):593-594.
23. Arico M., Schrappe M., Hunger S.P., et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010, 28(31):4755-4761.
24. Harrison C.J., Moorman A.V., Broadfield Z.J., et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 2004, 125(5):552-559.
25. Raimondi S.C., Zhou Y., Mathew S., et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 2003, 98(12):2715-2722.
26. Kuiper R.P., Schoenmakers E.F., van Reijmersdal S.V., et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007, 21(6):1258-1266.
27. Mullighan C.G. Single nucleotide polymorphism microarray analysis of genetic alterations in cancer. Methods Mol Biol 2011, 730:235-258.
28. Mullighan C.G., Downing J.R. Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol 2009, 46(1):3-15.
29. Kawamata N., Ogawa S., Zimmermann M., et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2008, 111(2):776-784.
30. Zhang J., Mullighan C.G., Harvey R.C., et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011, 118(11):3080-3087.
31. Weng A.P., Ferrando A.A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306(5694):269-271.
32. Gutierrez A., Sanda T., Grebliunaite R., et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009, 114(3):647-650.
33. Tosello V., Mansour M.R., Barnes K., et al. WT1 mutations in T-ALL. Blood 2009, 114(5):1038-1045.
34. O'Neil J., Grim J., Strack P., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007, 204(8):1813-1824.
35. Dobbins S.E., Sherborne A.L., Ma Y.P., et al. The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia. Genes Chromosomes Cancer 2013, 52(10):954-960.
36. Parker H., An Q., Barber K., et al. The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes Chromosomes Cancer 2008, 47(12):1118-1125.
37. Virely C., Moulin S., Cobaleda C., et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia 2010, 24(6):1200-1204.
38. Heltemes-Harris L.M., Willette M.J., Ramsey L.B., et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med 2011, 208(6):1135-1149.
39. Iacobucci I., Lonetti A., Paoloni F., et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica 2010, 95(10):1683-1690.
40. Iacobucci I., Storlazzi C.T., Cilloni D., et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell' Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009, 114(10):2159-2167.
41. Martinelli G., Iacobucci I., Storlazzi C.T., et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009, 27(31):5202-5207.
42. Den Boer M.L., van Slegtenhorst M., De Menezes R.X., et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009, 10(2):125-134.
43. Georgopoulos K., Bigby M., Wang J.H., et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 1994, 79(1):143-156.
44. Chapiro E., Russell L., Lainey E., et al. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 2010, 24(3):642-645.
45. Hertzberg L., Vendramini E., Ganmore I., et al. Down syndrome acute lymphoblastic leukemia: a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the iBFM Study Group. Blood 2010, 115(5):1006-1017.
46. Flex E., Petrangeli V., Stella L., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008, 205(4):751-758.
47. Bercovich D., Ganmore I., Scott L.M., et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372(9648):1484-1492.
48. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009, 106:9414-9418.
49. Kearney L., Gonzalez De Castro D., Yeung J., et al. A specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukaemia. Blood 2008, 113:646-648.
50. Tasian S.K., Doral M.Y., Borowitz M.J., et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood 2012, 120(4):833-842.
51. Maude S.L., Tasian S.K., Vincent T., et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012, 120(17):3510-3518.
52. Harvey R.C., Mullighan C.G., Chen I.M., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115(26):5312-5321.
53. Harvey R.C., Mullighan C.G., Wang X., et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010, 116(23):4874-4884.
54. Cario G., Zimmermann M., Romey R., et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115(26):5393-5397.
55. Ensor H.M., Schwab C., Russell L.J., et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117(7):2129-2136.
56. Chen I.M., Harvey R.C., Mullighan C.G., et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012, 119(15):3512-3522.
57. Loh M.L., Zhang J., Harvey R.C., et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood 2013, 121(3):485-488.
58. Bersenev A., Wu C., Balcerek J., et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010, 120(6):2058-2069.
59. Weston B.W., Hayden M.A., Roberts K.G., et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 2013, 31(25):e413-e416.
60. Heerema N.A., Nachman J.B., Sather H.N., et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. Blood 1999, 94(12):4036-4045.
61. Pui C.H., Williams D.L., Raimondi S.C., et al. Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1987, 70(1):247-253.
62. Powell B.C., Jiang L., Muzny D.M., et al. Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr Blood Cancer 2013, 60(6):E1-E3.
63. Shah S, Schrader KA, Waanders E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. In press. doi:10.1038/ng.2754.
64. Moorman A.V., Richards S.M., Robinson H.M., et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007, 109(6):2327-2330.
65. Robinson H.M., Harrison C.J., Moorman A.V., Chudoba I., Strefford J.C. Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage-fusion-bridge cycle. Genes Chromosomes Cancer 2007, 46(4):318-326.
66. Strefford J.C., van Delft F.W., Robinson H.M., et al. Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci U S A 2006, 103(21):8167-8172.
67. Moorman A.V., Robinson H., Schwab C., et al. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 Trials. J Clin Oncol 2013, 31(27):3389-3396.
68. Mullighan C.G., Miller C.B., Su X., et al. ERG deletions define a novel subtype of B-progenitor acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2007, 110(11):691.
69. Van Vlierberghe P., Palomero T., Khiabanian H., et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010, 42(4):338-342.
70. Van Vlierberghe P., Patel J., Abdel-Wahab O., et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia 2011, 25(1):130-134.
71. Todd M.A., Picketts D.J. PHF6 interacts with the nucleosome remodeling and deacetylation (NuRD) complex. J Proteome Res 2012, 11(8):4326-4337.
72. Wang J., Leung J.W., Gong Z., Feng L., Shi X., Chen J. PHF6 regulates cell cycle progression by suppressing ribosomal RNA synthesis. J Biol Chem 2013, 288(5):3174-3183.
73. Coustan-Smith E., Mullighan C.G., Onciu M., et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009, 10(2):147-156.
74. Inukai T., Kiyokawa N., Campana D., et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol 2012, 156(3):358-365.
75. Wood B., Winter S., Dunsmore K., et al. Patients with early t-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction-a Children's Oncology Group (COG) study. Blood (ASH Annual Meeting Abstracts) 2009, 114(22):9.
76. Rothenberg E.V., Moore J.E., Yui M.A. Launching the T-cell-lineage developmental programme. Nat Rev Immunol 2008, 8(1):9-21.
77. Korbel J.O., Campbell P.J. Criteria for inference of chromothripsis in cancer genomes. Cell 2013, 152(6):1226-1236.
78. Della Gatta G., Palomero T., Perez-Garcia A., et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med 2012, 18(3):436-440.
79. Van Vlierberghe P., Ambesi-Impiombato A., Perez-Garcia A., et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med 2011, 208(13):2571-2579.
80. Shochat C., Tal N., Bandapalli O.R., et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 2011, 208(5):901-908.
81. Zenatti P.P., Ribeiro D., Li W., et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011, 43(10):932-939.
82. Ntziachristos P., Tsirigos A., Vlierberghe P.V., et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012, 18(2):298-303.
83. Neumann M., Coskun E., Fransecky L., et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013, 8(1):e53190.
84. Neumann M., Heesch S., Gokbuget N., et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J 2012, 2(1):e55.
85. Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42(2):181-185.
86. Sneeringer C.J., Scott M.P., Kuntz K.W., et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010, 107(49):20980-20985.
87. Yap D.B., Chu J., Berg T., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117(8):2451-2459.
88. Simon C., Chagraoui J., Krosl J., et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012, 26(7):651-656.
89. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363(25):2424-2433.
90. Neumann M., Heesch S., Schlee C., et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 2013, 121(23):4749-4752.
91. Shi J., Wang E., Zuber J., et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene 2013, 32(7):930-938.
92. Neff T., Sinha A.U., Kluk M.J., et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A 2012, 109(13):5028-5033.
93. Kim W., Bird G.H., Neff T., et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 2013, 9(10):643-650.
94. De Keersmaecker K., Atak Z.K., Li N., et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet 2013, 45(2):186-190.
95. Yang J.J., Bhojwani D., Yang W., et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 2008, 112(10):4178-4183.
96. Kawamata N., Ogawa S., Seeger K., et al. Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. Int J Oncol 2009, 34(6):1603-1612.
97. Mullighan C.G., Phillips L.A., Su X., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322(5906):1377-1380.
98. Mullighan C.G., Zhang J., Kasper L.H., et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011, 471(7337):235-239.
99. Inthal A., Zeitlhofer P., Zeginigg M., et al. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia 2012, 26(8):1797-1803.
100. Pasqualucci L., Dominguez-Sola D., Chiarenza A., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471(7337):189-195.
101. Kino T., Nordeen S.K., Chrousos G.P. Conditional modulation of glucocorticoid receptor activities by CREB-binding protein (CBP) and p300. J Steroid Biochem Mol Biol 1999, 70(1-3):15-25.
102. Lambert J.R., Nordeen S.K. CBP recruitment and histone acetylation in differential gene induction by glucocorticoids and progestins. Mol Endocrinol 2003, 17(6):1085-1094.
103. Meyer J.A., Wang J., Hogan L.E., et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 2013, 45(3):290-294.
104. Tzoneva G., Perez-Garcia A., Carpenter Z., et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 2013, 19(3):368-371.
105. Faham M., Zheng J., Moorhead M., et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012, 120(26):5173-5180.
106. Venn N.C., van der Velden V.H., de Bie M., et al. Highly sensitive MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion. Leukemia 2012, 26(6):1414-1416.
107. Figueroa M.E., Chen S.C., Andersson A.K., et al. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Invest 2013, 123(7):3099-3111.
108. Geng H., Brennan S., Milne T.A., et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov 2012, 2(11):1004-1023.